Skip to main content
. Author manuscript; available in PMC: 2007 Sep 27.
Published in final edited form as: J Pain. 2007 May 29;8(8):637–649. doi: 10.1016/j.jpain.2007.04.004

Table 2.

Weight and blood glucose levels of diabetic and nondiabetic mice receiving 2-week intrathecal treatment with CSF, NGF, or GDNF starting 3 weeks post-STZ. Weight is in grams; glucose levels are mmol/L. Data represented as means +/− standard error of mean. Statistical analysis did not reveal an effect of treatment on weight or blood glucose.

Pre-Treatment Post-Treatment
Diabetic
CSF Weight 19.0 +/− 0.91 18.5 +/− 1.66
Glucose 22.6 +/− 0.93 26.3 +/− 0.56
NGF Weight 19.3 +/− 0.42 20.3 +/− 0.97
Glucose 24.8 +/− 0.88 26.2 +/− 0.61
GDNF Weight 20.0 +/− 1.00 19.3 +/− 1.20
Glucose 23.6 +/− 0.94 26.8 +/− 0.39
Nondiabetic
CSF Weight 22.5 +/− 0.65 24.5 +/− 0.50
Glucose 8.2 +/− 0.16 8.5 +/− 0.70
NGF Weight 22.8 +/− 0.48 23.8 +/− 0.48
Glucose 8.5 +/− 0.57 6.5 +/− 1.29
GDNF Weight 21.5 +/− 0.65 24.3 +/− 0.25
Glucose 8.1 +/− 0.48 6.7 +/− 1.35